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Background: Immediate evaluation is possible for the percutaneous 
CT-guided cryosurgery by estimation of Hounsﬁeld units, the size of 
formed ice-ball, and the percentage of tumor area covered by ice-ball. 
But, this method is not useful for the patient underwent ﬂuoroscopy-
guided or video-assisted thoracosopic cryosurgery. And, the majority 
of the lesions are turned into cavitary lesion or necrotic area in the 
early postoperative periods. So, the aim of this study is to identify the 
methods and ideal time for the evaluation of the completeness of cryo-
therapy in an attempt to quantify initial treatment success.
Methods: 52 pulmonary tumors in 34 consecutive patients (29 men and 
5 women, median age 63 years, age range; 25-80 years) were treated by 
cryosurgery. Of the 52 pulmonary masses, 29 masses were primary lung 
cancers, and 23 masses were metastatic lung cancers. Cryosurgery was 
performed under computed tomographic, ﬂuoroscopic or video-assisted 
thoracoscopic guidance. Cryoablation was performed as one or two cy-
cles of 20-minute freeze followed by 5-minute thaw. Follow up chest CT 
scanning was taken at postoperative 1 month, 3 months and 6 months. 
We measured the area and Hounsﬁeld units of the mass with computed 
tomography. And we compare the measured value respectively.
Results: The measured area of the mass is ranged from 141.8mm2 to 
3996.8mm2 preoperatively (postoperative 1 month; 66.8-8481.8mm2, 3 
months; 32.6-4841.7mm2, 6 months; 45.6-4572.2mm2). The Hounsﬁeld 
unit is ranged from 32 to 98 preoperatively (postoperative 1 month; 8-
71, 3 months; 24-68, 6 months; 26-98). And, the decrease of the Houn-
sﬁeld unit of 1 month showed good correlation of the reduction of the 
area of mass at postoperative 6 months (p-value=0.14). On the contrary, 
between the change of the Hounsﬁeld unit and the change of the area of 
mass at 3 months or 6 months showed no correlation statistically.
Conclusion: Postoperative computed tomographic scanning with mea-
surement of Hounsﬁeld unit at postoperative 1 month may be useful 
for the evaluation of the completeness of cryotherapy in an attempt to 
quantify initial treatment success.
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Background: Cryoablation for lung tumors is minimally invasive with 
median hospital stay of 2.6 days after treatment. However, local recur-
rences have occurred in 30% of treated tumors. In the present study, we 
analyzed the potential factors affecting local recurrence.
Materials and Methods: 173 tumors in 63 patients were followed up 
for more than 6 months after cryoablation. In these patients, 3 indices 
were examined. The diameter of tumors, distance between tumor and 
vessels 3 mm or larger, and the extent of the high density area (HDA) 
appearing after treatment which covers the tumor. Follow-up CT scan 
was taken every 3 months after treatment. Accumulated local control 
rate (LCR) was calculated by Kaplan Meier’s method.
Results: 173 tumors included 12 primary lung cancer and 161 meta-
static tumors with median diameter of 16.1mm. LCR 1 year after treat-
ment (1 year LCR) was 92% in 57 tumors of 10 mm or less in diameter, 
71% in 87 tumors of 11-20 mm, and 63% in 14 of 21-30 mm. 6 months 
LCR in 15 tumors of 30 mm or more in diameter was 47%. 1 year LCR 
in 106 tumors of 20 mm or less diameter devoid of large vessels within 
4 mm from the margin of the tumor was 88% and that in 35 tumor of 
20 mm or less with large vessels within 4 mm was 39%, signiﬁcantly 
lower (p<.0001). Among 140 tumors of 20 mm or less diameter with 
measurable HDA on CT scan after treatment, 120 with HDA covering 
whole tumor showed 83% of 1 year LCR and 20 with insufﬁcient HDA 
coverage showed signiﬁcantly lower LCR of 32% (p<.0001). Signiﬁ-
cant correlation between the distance from large vessels and sufﬁcient 
HDA was shown (Fisher’s test; p=.014).
Conclusion: Tumor diameter over 31mm, 4 mm or nearer to large ves-
sels (3 mm or more diameter), and insufﬁcient high density area (not 
covering whole tumor) were poor prognostic factors for crypablation 
against malignant pulmonary tumors.
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Background: Many patients with lung cancer cannot undergo chemo-
therapy or radiation therapy due to impaired pulmonary function or 
poor general performance status. Most of them show resistance to these 
treatments, resulting in continued tumor growth and spreading. In such 
patients, minimally invasive treatments directed to local tumors may 
relieve patients from cancer pain or other generalized symptoms. As 
cryosurgery has been proven to be effective and also safe for cancers 
in prostate, kidneys, liver and endobronchial obstructive tumors, we 
sought to evaluate our results and safety of cryosurgery for lung cancer.
Methods: At our hospital, from October, 2004 to December, 2005, 28 
patients were treated by cryosurgery. The average age of the patients 
was 59.8. Of the 28 patients, 18 had primary lung cancer, and 10 had 
metastatic lung cancers. The average tumor size was 49.9mm. Cryosur-
gery was performed using a cryoprobe under CT guidance using local 
anesthesia. Follow up chest CT scan was taken at post operative day 
on 1 week, 1mo, 3mo and 6 months, and surgical ﬁnal outcome was 
evaluated according to RECIST (complete remission, partial remission, 
stable disease, and progression). 
Results: There were no procedure related mortalities. Postoperative 
pleural effusion was noted in 1 case (3.5%) and there were 9 cases 
(32%) of pneumothorax of which 3 needed closed thoracostomies. 
Small amounts of blood tinged sputum was noted by 15 of the patients 
(53.6%). Of the 28 patients, 3 patients (10.7%) showed complete remis-
sion and six (21.4%) resulted in disease progression. 21 patients (75%) 
of the patients exhibited response to the cryosurgical procedure. 
Conclusions: Cryosurgery for lung cancer can be performed safely 
under local anesthesia, and patients can be discharged early without se-
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rious complications. The effectiveness in local tumor destruction makes 
cryosurgery a promising option for the treatment of local tumors in 
patients with impaired pulmonary function, poor general performances, 
or those who refuse to take surgery
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Introduction: Malignant pleural effusion is a very common clinical 
manifestation of different neoplasms. Correct diagnosis in patients 
with malignant pleural effusion sometimes is difﬁcult. Treatment of 
patients with primary (mesothelioma) and metastatic pleural spread is 
mostly palliative. The study was aimed to deﬁne diagnostic value of 
ﬂuorescence thoracoscopy and photodynamic therapy in patients with 
malignant pleural effusions.
Materials and Methods: 41 patients with malignant pleural effusion 
were treated in our clinic using photodynamic therapy. Mesothelioma 
was diagnosed in 10, pleural metastases of different malignant tumors 
in 31 patients. Thoracoscopy was performed to 21 patients, thoracoto-
my - to 10 patients. Multifocal pleural biopsy was performed to conﬁrm 
diagnoses histologicaly. Eight patients underwent thoracoscopic ﬂuo-
rescence diagnostic with 5-aminolaevulinic acid (5-ALA “Alasens”). 
In cases of diffuse malignant mesothelioma parietal pleuroectomy was 
routinely performed. Photodynamic therapy was done after debulk-
ing surgery and then continued after operation through diffusers (3-5) 
inserted into thoracic cavity. “Photosense” (0,3-0,5 mg/kg in 100 ml of 
isotonic natrium chloride solution) was used for photodynamic therapy 
intrapleuraly or intravenously. Five courses of prolonged photodynamic 
therapy were performed to each patient postoperatively. 
Results: Pleural spread was conﬁrmed by histologic examination in all 
patients. Additional pleural lesions, not visible by white light thoracos-
copy, were found in 4 (50,0%) patients during ﬂuorescence thoracos-
copy and conﬁrmed histologicaly in all cases. Photodynamic therapy 
considered to be effective: effusion accumulation decreased and then 
stopped in 39 (95,1%) of patients; pain relief - in 32 (78,1%). Two 
patients needed repeated chest tube drainage and courses of photody-
namic therapy with positive results. Median follow-up was 14,3 months 
varies from 3 to 45 months. No recurrence of pleural effusion was 
detected during follow-up period.
Conclusion: Videothoracoscopy is an effective diagnostic method 
in deﬁnition of pleural effusion etiology; ﬂuorescence thoracoscopy 
increases diagnostic abilities of standard thoracoscopy; photody-
namic therapy of malignant pleural effusions permits to achieve good 
short-term results and improve quality of life in that complex group of 
patients.
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Introduction: Premeditated combination therapy with both surgical 
resection and radiofrequency ablation (RFA) has not been previously 
reported. We report our experience with combined CT-guided RFA and 
surgical resection in three patients with metastatic pulmonary tumors.
Patients and Methods: Percutaneous RFA was performed in patients 
with intrathoracic malignancies between June 2001 and April 2006 in 
Okayama University Hospital. A total of 229 patients underwent 389 
RFA sessions applied for 637 lesions. Of the 229 patients considered, 
188 patients who received RFA had metastatic pulmonary lesions, 
while 41 patients had primary lung carcinomas. There were 88 patients 
(38.4%) who had experiences of thoracic surgery before RFA. In this 
series, we experienced three cases which underwent combined therapy 
with surgical resection and RFA. Two cases of them had metastatic 
lesions on both sides of lungs, we performed surgical resection for one 
side and RFA for contralateral side due to avoid high-invasiveness by 
bilateral thoracotomy. We also experienced a case which underwent 
surgical resection on the part of a string of tumors and RFA on the part 
of solitary tumors to avoid high-invasiveness by right pneumonectomy. 
Results: No pneumothoraces were seen for two patients after RFA, 
whereas the third patient was suffered from triﬂing pneumothorax 
needless to add any treatments. No other complications or side effects 
such as pleural effusion, pleurisy, relevant bleeding, high fever, or 
severe pain require medication occurred during and after RFA for all 
three patients. There were also no complications or side effects after 
surgery, and all patients could go back to their daily lives almost as 
same as theirs before these combined therapy.
The ﬁrst patient remained asymptomatic on clinical examination about 
9 months after the ﬁrst RFA, however, contrast-enhanced CT scans 
revealed a right hilar lymph nodal swelling and re-growth with partial 
enhancement of the ablated tumor, a repeated RFA was performed 
in this same region. After the re-RFA, he has been receiving chemo-
therapy (CDDP + S-1), and he is alive with right hilar lymph nodes and 
pulmonary metastases about three and a half years after the combina-
tion therapy without any evidence of viability of ablated tumor.
In the second patient, follow-up CT scans obtained three months after 
RFA showed novel three metastatic tumors on both sides of the lungs 
without any signs of tumor progression. Therefore he underwent 
repeated RFA for these three tumors. CT scans obtained ﬁve months 
after the second RFA revealed some pleural dissemination in the right 
pleural cavity. He underwent embolization of the inferior phrenic arter-
ies, and he is alive with tumors (disseminations) about a year and eight 
months after the combination therapy. 
The third patient is alive and well without any signs of recurrence or 
metastases about nine months after the combination therapy.
Conclusions: By understanding the advantage and disadvantage of 
RFA and surgical resection, the combination therapy with these modali-
